Douglas J. Pitt-Fraser

Silverburn Crescent, Bridge Of Don
Aberdeen, SCT AB238EW, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection.

Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection.

Journal: Biochemical and biophysical research communications

Published: June 12, 2023

Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa.

Cysteamine Inhibits Glycine Utilisation and Disrupts Virulence in Pseudomonas aeruginosa.

Journal: Frontiers in cellular and infection microbiology

Published: May 31, 2021

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial.

Journal: PloS one

Published: July 10, 2020

Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection.

Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection.

Journal: Infection and immunity

Published: December 22, 2017

Rapid and robust analytical protocol for E. coli STEC bacteria subspecies differentiation using whole cell MALDI mass spectrometry.

Rapid and robust analytical protocol for E. coli STEC bacteria subspecies differentiation using whole cell MALDI mass spectrometry.

Journal: Talanta

Published: October 13, 2017

Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.

Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.

Journal: Antimicrobial agents and chemotherapy

Published: June 15, 2016

An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis.

An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis.

Journal: Clinical drug investigation

Published: May 08, 2016

Cystic fibrosis - a multiorgan protein misfolding disease.

Cystic fibrosis - a multiorgan protein misfolding disease.

Journal: Future science OA

Published: September 01, 2015

Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum.

Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum.

Journal: EBioMedicine

Published: July 07, 2015

Progress towards next-generation therapeutics for cystic fibrosis.

Progress towards next-generation therapeutics for cystic fibrosis.

Journal: Future medicinal chemistry

Published: July 29, 2014

Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis.

Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis.

Journal: Orphanet journal of rare diseases

Published: July 07, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026